Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-1293
- Development stage
- Preclinical
- Lead developer
- National Cancer Institute
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Hydrogel Systems → Drug Delivery Systems
- Administration
- Local
01
Overview
microRNA-1293 (miR-1293) is a tumor-suppressive microRNA being investigated for the treatment of diffuse pleural mesothelioma (DPM), particularly in cases characterized by NF2 loss or Hippo pathway disruption. It functions by targeting the S100A16-centered Hippo/EMT axis, leading to the downregulation of S100 calcium binding protein A16 (S100A16), YAP, TAZ, and TEAD, as well as markers of epithelial-mesenchymal transition (EMT). miR-1293 re-expression induces apoptosis and cell-cycle arrest in mesothelioma cells. For therapeutic delivery, it has been formulated in a silk fibroin hydrogel (SFH-miR-1293) for local administration, which has demonstrated significant anti-tumor activity and survival benefits in preclinical orthotopic models.
02
Targets
Apurinic/apyrimidinic endonuclease 1 mRNAPOLD4 (DNA polymerase delta subunit 4)Replication protein A 70 kDa DNA-binding subunit mRNAS100A16 (S100 calcium-binding protein A16)
Beyond the preview
Go deeper on microRNA-1293.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microRNA-1293.